Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Novartis

    - PMLiVE

    Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

    Around 9,000 people in the US currently live with SMA

    - PMLiVE

    Novartis announces plans for new US manufacturing hub

    The US hub is expected to create 700 new jobs by 2030

    - PMLiVE

    Novartis reports primary endpoint reached in phase 3 malaria trial

    The treatment demonstrated non-inferiority to current standard of care

    - PMLiVE

    Novartis presents new positive data for rheumatic autoimmune disease treatment

    Patient outcome benefits were observed in two ongoing phase 3 trials

    - PMLiVE

    Novartis to acquire Avidity Biosciences in deal worth $12bn

    The acquisition will expand Novartis’ neuroscience pipeline

    - PMLiVE

    Novartis announces new data supporting MS therapy Kesimpta

    The latest trial results reinforce the drug's long-term efficacy and safety profile

    - PMLiVE

    Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

    Novartis will gain cardiovascular treatment option pacibekitug

    - PMLiVE

    Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

    The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

    - PMLiVE

    Roche’s Evrysdi tablets approved by MHRA to treat spinal muscular atrophy

    It is hoped the new formulation will offer patients greater freedom and flexibility compared to the liquid version

    - PMLiVE

    Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

    The companies will focus on inflammatory diseases that have been historically difficult to treat

    - PMLiVE

    Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

    The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

    - PMLiVE

    Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

    The companies will aim to discover and develop new therapeutics for the group of disorders

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links